BC43 Inter-amer 30

RNS Number:2569T
Lilly (Eli) & Co
19 March 2002


Date: March 19, 2002



For Release: EMBARGOED UNTIL 3:00 P.M. EDT, MARCH 19, 2002

Refer to: (317) 651-3710 - David Shaffer (Lilly)
                (917) 887-5102 - Jessica Colon (MS&L)
                (917) 533-5998 - Glenn Lehrman (MS&L)

    Data Released at the American College of Cardiology Meeting Support the
Demonstrated Life-Saving Benefits of ReoPro(R) in Treating Heart Attack Patients

Atlanta, GA - Results of numerous studies show that treating patients with the
anti-platelet drug ReoPro(R) (abciximab) following a heart attack helps increase
blood flow to the heart, thus reducing patients risk of death, recurrent heart 
attack, and the need to re-open clogged arteries.

The data, presented at the 51st annual meeting of the American College of
Cardiology (ACC), highlight the strength of ReoPro in treating patients with
diabetes, visible and non-visible thrombus (blood clots), and complex lesions
(arteries with multiple blockages).

In particular, a study presented by Dr. Albert Schomig, Deutsches Herzzentrum,
Munich, Germany, just published in the March 16 edition of The Lancet, the
combination of ReoPro and a stent appeared to significantly limit further damage
to the heart muscle compared with a combination of ReoPro and a thrombolytic
(clot buster).(1),(2) Other data presented by Dr. Mahesh Mulumudi of the Ochener
Medical Institution, New Orleans, suggested that ReoPro improved blood
circulation to the heart, as measured by Myocardial Blush Grade (MBG), a
sensitive indicator of future heart problems.(3) Diabetic patients experienced a
particularly beneficial effect with ReoPro treatment.

A separate analysis examining left ventricular (LV) function (impaired LV
function can often lead to heart failure and death) in 47 patients who underwent
angioplasty, led by Dr. Anna Petronio of the University of Pisa, Pisa, Italy,
reported that treatment with ReoPro helped to maintain blood flow to the heart
muscle and improved heart muscle function at both 30 days and six months.(4)

"ReoPro has consistently demonstrated an ability to not only prevent blood
clots, but also improve microvascular perfusion and myocardial blood flow, all
of which enhance long-term clinical outcomes," said Dr. Dean Kereiakes, Medical
Director, The Carl and Edyth Lindner Center for Research and Education, and CEO
of The Ohio Heart Health Center, Cincinnati, Ohio.

Two additional presentations from the GUSTO V (Global Use of Strategies to Open
Occluded Arteries in Acute Myocardial Infarction) trial that studied the
potential use of ReoPro in combination with a thrombolytic as an alternative
treatment option for heart attack patients. The first, presented by Dr. Magnus
Ohman of Duke University, Durham, North Carolina, reported that patients treated
with the combination of ReoPro and the thrombolytic RETAVASE(R) (reteplase) were
34 percent less likely to experience a recurrent heart attack than patients
treated with Retavase alone (2.3% vs. 3.5%, respectively).(5)  A second GUSTO V
presentation, by Dr. Mitchell Krucoff of Duke University, reported that the
ReoPro and RETAVASE combination restored overall blood flow more quickly and
improved the stability of the target vessel.(6)

About ReoPro

ReoPro is a member of a class of drugs known as glycoprotein (GP) IIb/IIIa
inhibitors that target the platelet component of blood clots and reduce the
complications associated with blood flow restrictions during coronary
intervention, including angioplasty and stenting.  ReoPro blocks the formation
of thrombus, helping to restore or maintain flow in the coronary arteries.
Giving patients ReoPro while they undergo procedures to open their arteries has
been proven to reduce the risk of death or heart attack.  ReoPro has
demonstrated this benefit at 30 days, six months and one year.  In addition,
Phase III study results from the EPISTENT trial have demonstrated that using
ReoPro in combination with stents reduces the risk of death by 57 percent one
year after percutaneous coronary intervention (PCI) compared to stents alone.
Importantly, in a pooled-analysis of three phase III trials ReoPro has been
shown to lower the one-year mortality rate of diabetes patients undergoing PCI,
who are at particularly high risk for complications, to a rate similar to that
of non-diabetics.

ReoPro, derived from a monoclonal antibody, c7E3 Fab, takes a unique approach to
preventing blood clots by targeting the GP IIb/IIIa receptors and binding to
them, inhibiting platelet aggregation and reducing thrombin generation.  ReoPro
is currently indicated as an adjunct to PCI for the prevention of cardiac
ischemic complications in patients undergoing PCI and in patients with unstable
angina not responding to conventional medical therapy when PCI is planned within
24 hours.

More than one million patients have been treated with ReoPro.  It has been
studied more extensively than any other GP IIb/IIIa inhibitor and it has
consistently demonstrated durable and robust clinical efficacy over the
long-term.

ReoPro has the potential to increase the risk of bleeding, particularly in the
presence of anticoagulation such as heparin or a clot-buster.  Full prescribing
information for ReoPro is available at www.reopro.com, or by calling
1-800-545-5979.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of best-in-class pharmaceutical products by applying the latest
research from its own worldwide laboratories and from collaborations with
eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly
provides answers - through medicines and information - for some of the world's
most urgent medical needs.  Additional information about Lilly is available at
www.lilly.com.

                            #          #          #


ReoPro(R) (abciximab, Centocor, Lilly)

RETAVASE(R) (reteplase, Centocor)

--------------------------


(1) Schomig A, et. al. Clinical Outcomes of Patients with Acute Myocardial
Infarction Randomized Either Coronary Stenting Plus Abciximab or Fibrinolysis
Plus Abciximab (STOPAMI-2 Trial). The Journal of the American College of
Cardiology, Vol 39, No. 5 (Supplement A): 2002.

(2) Kastrati A, et. al. Myocardial Salvage After Coronary Stenting Plus
Abciximab Versus Fibrinolysis Plus Abciximab in Patients with Acute Myocardial
Infarction: A Randomised Trial. The Lancet, Vol. 359, March 16, 2002.

(3) Mulumudi MS, et. al. Role of Abciximab in the Preservation of Myocardial
Microcirculation During Mechanical Reperfusion For Acute ST-Segment Elevation
Myocardial Infarction. The Journal of the American College of Cardiology, Vol
39, No. 5 (Supplement A): 2002.

(4) Petronio AS, et. al. Microcirculation Recovery After Primary Coronary
Angioplasty in Patients with Acute Myocardial Infarction Treated with Abciximab
or Intracoronary Adenosina. The Journal of the American College of Cardiology,
Vol 39, No. 5 (Supplement A): 2002.

(5) Ohman EM, et. al. Prevention of Reinfarction Using Half-Dose Reteplase and
Abciximab: Observations From the GUSTO 5 Trial. The Journal of the American
College of Cardiology, Vol 39, No. 5 (Supplement A): 2002.

(6) Krucoff MW, et. al. The Abciximab ST-Recovery ON AMI (ASTRONAMI) GUSTO V
Substudy: Enhanced Early Speed, Stability, Quality of Reperfusion with
Anti-platelet Augmented Thrombolytic Therapy for ST-Elevation AMI. The Journal
of the American College of Cardiology, Vol 39, No. 5 (Supplement A): 2002.



                      This information is provided by RNS
            The company news service from the London Stock Exchange

Inter-amer 30 (LSE:BC43)
Gráfico Histórico do Ativo
De Mar 2025 até Abr 2025

Inter-amer 30 (LSE:BC43)
Gráfico Histórico do Ativo
De Abr 2024 até Abr 2025